Recipients identified as high-risk–specifically those exposed to T-cell-depleting monoclonal antibodies or prolonged high-dose corticosteroids, and those with persistent lymphopenia (particularly CD4+ count < 200 cells/μL)–require extended and proactive ophthalmologic surveillance for 9–12 months. This evidence concerns the gene CD4 and lymphopenia.